

Molecular diversity and extended spectrum beta-lactamase resistance of diarrheagenic *Escherichia coli* from patients attending selected health care facilities in Nasarawa State, Nigeria

ABSTRACT

Aims: This study investigated the molecular diversity and extended spectrum beta-lactamase resistance of diarrheagenic *E. coli* isolated from patients attending selected healthcare facilities in Nasarawa State, Nigeria.

Place and Duration of Study: Department of Microbiology, Nasarawa State University, P.M.B 1022, Keffi, Nasarawa State, Nigeria; between December 2017 and June, 2019.

Methodology: A total of 207 confirmed *E. coli* isolates (using standard microbiological methods) from loose stool samples of patients with suspected cases of diarrhea (69 from Federal Medical Centre Keffi [MCK] 69 from General Hospital Akwanga [GHA] and 69 from Dalhatu Araf Specialist Hospital Lafia [DASHL]) were included in this study. **Results:** Phenotypic detection of ESBL production by β -lactam resistant isolates was done using double disc synergy test. Molecular detection of ESBL genes in phenotypically confirmed ESBL producers was done using Polymerase Chain Reaction. Out of 56 isolates jointly resistant to cefotaxime and/or ceftazidime and ciprofloxacin from DASHL, FMCK and GHA, 53.6% (30/56) were ESBL producers, distributed in relation to the hospitals as follows: *bla*_{CTX-M} in DASHL was 6(66.7%), FMCK was 11(100.0%), and GHA was 10(100.0%); *bla*_{SHV} in DASHL was 8(88.9%), FMCK was 7(63.6%), and GHA was 10(100.0%), and *bla*_{TEM} in DASHL was 9(100.0%), FMCK was 10(90.9%), and GHA was 10(100.0%). Also, the occurrence of *bla*_{SHV} was 100.0% in GHA but 88.9% in DASHL. The detection DEC was high in DASHL (88.9%) but low in GHA (58.8%). The occurrence of ETEC was high in GHA (60.0%) while EAEC was also high in FMCK (81.8%) and GHA (70.0%). The isolates were distributed into strain A – J based on RFLP pattern and the occurrence of strain A was high in GHA (70.0%) but low in DASHL (33.3%). **Conclusion:** Most of the isolates were both diarrheagenic and ESBL resistant, and the predominant ESBL and pathotypes genes were *bla*_{CTX-M}, *bla*_{TEM} and EAEC. Further studies on molecular detection of sub-types of ESBL and sequencing of diarrheagenic pathotypes genes should be carried out.

1. INTRODUCTION

Diarrhea is defined as the passage of three or more loose or liquid stools per day (or more frequent passage than is normal for the individual); frequent passing of formed stools is not diarrhea, nor is the passing of loose, "pasty" stools by breastfed babies [1].

Common causes of diarrhea in humans include: Rotavirus, *Salmonella* spp., *Shigella* spp., *Campylobacter jejuni*, *Entamoeba histolytica*, and *Giardia lamblia* [2]. The bacterial causes, *Escherichia*

42 *coli* (*E. coli*) has been implicated more frequently [3,4]. Worldwide, reports have shown that *E. coli* causing
43 diarrhea, so-called diarrhoeagenic *Escherichia coli* (DEC), belong to six pathotypes namely:
44 enteroaggregative *Escherichia coli* (EAEC), Enteroinvasive *Escherichia coli* (EIEC) Enterohemorrhagic
45 *Escherichia coli* (EHEC)/Shiga-toxin producing *Escherichia coli* (STEC), enteropathogenic *Escherichia*
46 *coli* (EPEC), enterotoxigenic *Escherichia coli* (ETEC) and diffusely adherent *Escherichia coli* (DAEC) [5,
47 6, 7]. Among the DEC pathotypes, EAEC along with the well-established ETEC and EPEC cause a
48 substantial health burden of infant diarrheal cases and a variety of animal's species [8]. Mostly, DEC
49 outbreaks are often found to be associated with direct contact with infected animals or indirectly through
50 consumption of vegetables, fruits, and water contaminated with infected animal feces [9, 10]. This study
51 thus focused on molecular diversity and extended spectrum beta-lactamase resistance of diarrheagenic
52 *E. coli* isolated from patients attending selected healthcare facilities in Nasarawa State, Nigeria.

53 2. MATERIAL AND METHODS

54 2.1 Sample Collection

55 A total of 207 (69 from Federal Medical Centre Keffi, 69 from General Hospital Akwanga and 69 from
56 Dalhatu Araf Specialist Hospital Lafia) loose stool samples of patients with suspected cases of diarrhea
57 were randomly collected over a period of three (3) months using sterile container and transported using
58 ice pack to Microbiology Laboratory, Nasarawa State University, Keffi for analysis. The consents of the
59 suspected diarrheic patients were obtained before sample collection.
60
61

62 2.2 Isolation and Identification of *Escherichia coli*

63 *Escherichia coli* were isolated from loose stool samples of patients with suspected cases of diarrhea: With
64 the aid of a wire loop, the stool sample was streaked on MacConkey agar (Oxoid Ltd., Basingstoke, UK)
65 plate and incubated at 37°C for 24 h. Pinkish colonies that grew on MacConkey agar were further
66 inoculated on Eosin Methylene Blue agar (Oxoid Ltd., Basingstoke, UK) and incubated at 37°C for 24 h.
67 Greenish metallic sheen colonies that grew on the Eosin Methylene Blue agar plate were selected as
68 presumptive *E. coli* based on method already described [11]. Presumptive *E. coli* were identified by
69 microscopical (Gram stain) and minimum biochemical tests for *E. coli* identification namely "IMViC"
70 (Indole, Methyl red, Voges-Proskauer, Citrate). Indole positive, Methyl red positive, Voges-Proskauer

71 negative and citrate negative isolates were further confirmed as *E. coli* using a commercial kit B004HI™
72 (HiMedia Ltd, India) in accordance with the manufacturer's instructions. The bacterium was stored in the
73 refrigerator at 4°C on nutrient agar slants and reactivated by sub-culturing on MacConkey agar and used
74 in the further experiments.

75 **2.3 Antimicrobial Susceptibility Testing**

76 Antimicrobial susceptibility testing of the confirmed *E. coli* isolates was carried out as earlier described [8].
77 Briefly, (3) pure colonies of isolated *E. coli* from loose stool samples of patients with suspected cases of
78 diarrhea was inoculated in to 5 ml sterile 0.85% (w/v) NaCl (BDH Chemicals Ltd., England) and the
79 turbidity of the bacteria suspension was adjusted to the turbidity equivalent to 0.5 McFarland's standard.
80 The McFarland's standard was prepared as follows; 0.5 ml of 1.172% (w/v) BaCl₂·2H₂O (BDH Chemicals
81 Ltd., England) was added into 99.5 ml of 1% (w/v) H₂SO₄ (BDH Chemicals Ltd., England).

82 A sterile swab stick was soaked in the standardized bacteria suspension and streaked on Mueller- Hinton
83 agar (Oxoid Ltd., Basingstoke, UK) plates and the antibiotic discs (Oxoid Ltd., Basingstoke, UK) were
84 aseptically placed at the center of the plates and allowed to stand for 1 h for pre-diffusion. The plates
85 were placed in an incubator (Model 12-140E, Quincy Lab Inc.) set at 37°C for 24 h. The diameter zone of
86 inhibition in millimeter was measured and the result of the susceptibility was interpreted in accordance
87 with the susceptibility break point earlier described [12].

88 **2.4 Extended Spectrum β-Lactamase (ESBL) Production Test**

89 The confirmatory test for Extended Spectrum β-Lactamase (ESBLs) Production against *E. coli* isolates
90 jointly resistance to cefotaxime, ceftazidime and ciprofloxacin was carried using two-disc method earlier
91 described [13]. Briefly, 10⁵ CFU *E. coli* suspensions jointly resistance to cefotaxime, ceftazidime and
92 ciprofloxacin were streaked on sterilized Mueller Hinton agar plates and Amoxicillin-clavulanic acid
93 (30µg) disc was placed in the centre of the plate and cefotaxime (30µg), cefpodoxime (10µg), ceftaxidime
94 (30µg) and ceftriaxone (30µg) disks were placed 15mm (edge-to-edge) from the centre disc.
95 Enhancement of zone of inhibition in the area between the amoxicillin-clavulanic acid disc and any one of
96 the β-lactam disks in **comparison** with the zone of inhibition on the far side of the drug disc was
97 interpreted as indicative of the presence of an ESBL in the test strain.

98 **2.5 Molecular Detection of ESBL genes**

99 **2.5.1 DNA Extraction**

100 The DNAs of *E. coli* isolates that were ESBL-positive by DDST confirmatory test was extracted by a
101 method described previously with minor modifications [14]. Briefly, a sweep of five *E coli* colonies plated
102 on LBA plates was taken, mixed with 200 µl of double-distilled water in 1.5-ml microcentrifuge tubes and
103 boiled for 10minutes in a water bath followed by snap chilling in ice for 5 min. The heat-treated bacterial
104 suspensions were centrifuged at 10000 rpm for 5 min to pellet down the cell debris, and the supernatants
105 were used as DNA templates in the PCR.

106 **2.5.2 Amplification of Primers:**

107 Primers (as in Table 1)for the ESBL genes were amplified by PCR method[9]. Reaction mixtures in final
108 volume of 25 µl was prepared with 10 pmol of each primer,200 mM of dNTP, 1 unit of Taq polymerase,
109 2.5 µl of 10Xreaction buffer, 1.5 mM MgCl₂in final concentration, and100 ng DNA template. Amplification
110 reactions was carried out in a thermocycler (Eppendorf master cycler, MA) under the following conditions:
111 94°C for 5min, followed by 30cycles of 94°C for 25sec, 52°C for 40sec, 72°C for 50sec, and72°C for 6min
112 for the final elongation step.

113 **2.5.3 Amplification of Diarrheagenic *Escherichia coli* Genes**

114 The amplification of DEC genes was done by mPCR assay of the DNA extracted from *E. coli* isolates as
115 described [9]. The DNA templates were subjected to multiplex PCR with specific primers for the detection
116 of the following virulence markers: *eaeA*(structural gene for intimin of EHEC and EPEC), *bfpA*(structural
117 gene for the bundle-forming pilus of EPEC), *vt1* and/or *vt2* (Shiga toxins 1 and 2 of EHEC), *eltB* and/or
118 *estA*(enterotoxins of ETEC), *ial*(invasion-associated locus of the invasion plasmid found in EIEC and
119 *Shigella*) and *pCVD* (the nucleotide sequence of the EcoRI-PstI DNA fragment of *pCVD432* of EAEC) as
120 shown in Table 2.

121 The mPCRs was performed with a 25 µl reaction mixture containing 5 µl of template DNA, 0.2 µl of 18x
122 PCR buffer II, 1.6 µl of a 1.25 mM mixture of deoxynucleoside triphosphates, 1.6 µl of 25 mM MgCl₂, 0.1
123 µl of 5 U of AmpliTaq Gold DNA polymerase per µl and a 0.2 µM concentration of each primer except

124 primer VT1, which was used at a concentration of 0.4 μM .The thermocycling conditions used are as
125 follows: 95°C for 5 min (Initial denaturation), 94°C for 20 sec. (denaturation) 55°C for 30 sec. (Annealing)
126 and 72°C for 30 sec. (initial extension) for 30 cycles, with a final 7 min extension at 72°C [9].

UNDER PEER REVIEW

128 **Table 1:** Primers and target genes with amplicon sizes for Extended Spectrum Beta-lactamase gene in *Escherichia coli*


S/N	Target genes	Gene sequence	Amplicon size	References
1	<i>bla_{TEM}</i>	5'-TCGGGGAAATGTGCGCG-3' 5'-TGCTTAATCAGTGAGGCACC-3'	972	[15]
2	<i>bla_{SHV}</i>	5'-GGGTTATTCTTATTTGTCGC-3' 5'-TTAGCGTTGCCAGTGCTC-3'	615	[15]
3	<i>bla_{CTX-M}</i>	5'-ACGCTGTTGTTAGGAAGTG-3' 5'-TTGAGGCTGGGTGAAGT-3'	857	[15]

129 **Table 2: Primers and amplicon size of diarrheagenic *Escherichia coli* pathotypes that was used [8]**

Primer	Target gene	Primer sequence	Amplicon size (bp)	Reference
LT	<i>eltB</i>	5'-TCTCTATGTGCATACGGAGC-3' 5'-CCATACTGATTGCCGCAAT-3'	322	[16]
ST	<i>estA</i>	5'-GCTAAACCAGTAGAGGTCTTCAAAA-3' 5'-CCCGGTACAGAGCAGGATTACAACA-3'	147	[16]
VT1	<i>vt1</i>	5'-GAAGAGTCCGTGGGATTACG-3' 5'-AGCGATGCAGCTATTAATAA-3'	130	[16]
VT2	<i>vt2</i>	5'-ACCGTTTTTTCAGATTTTGACACATA-3' 5'-TACACAGGAGCAGTTTCAGACAGT-3'	298	[16]
Eae	<i>eaeA</i>	5'-CACACGAATAAACTGACTAAAATG-3' 5'-AAAAACGCTGACCCGCACCTAAAT-3'	376	[16]
SHIG	<i>lial</i>	5'-CTGGTAGGTATGGTGAGG-3' 5'-CCAGGCCAACAATTATTTCC-3'	320	[16]
BfpA	<i>bfpA</i>	5'-TTCTTGGTGCTTGCGTGTCTTTT-3' 5'-TTTTGTTTGTGTATCTTTGTAA-3'	267	[16]
EA	<i>pCVD</i>	5'-CTGGCGAAAGACTGTATCAT-3' 5'-CAATGTATAGAAATCCGCTGTT-3'	630	[16]

130 LT= Enterotoxigenic *E. coli* (ETEC); ST=Enterotoxigenic *E. coli* (ETEC);VT=Enterohemorrhagic *E. coli* (EHEC); Eae=Enterohemorrhagic *E. coli* (EHEC); SHIG=Enteroinvasive

131 *E. coli* (EIEC); BfpA=Enteropathogenic *E. coli* (EPEC); EA= Enteraggregative *E. coli* (EAEC) [16].



132 **Plate 1:** Multiplex PCR amplification of reference strains of diarrheagenic *E. coli* from pure cultures (Lane 1, *E. coli* ATCC 11775;
 133 lane2, EAEC 97R; lane 3, EIEC ATCC 43893; lane 4, EPEC ATCC 43887; lane 5, EHEC ATCC 43889; lane 6, EHEC ATCC 43890;
 134 lane 7, ETEC ATCC 35401; lane M, marker (1-kb DNA ladder; Gibco/BRL). Numbers on the right are in base pairs).
 135

136 **2.5.4 Amplification of 16S rRNA Gene**

137 The 16S rRNA genes of the ESBL producing isolates were amplified using the 27F: 5'-
 138 AGAGTTTGATCMTGGCTCAG-3' and 1492R: 5'-CGGTTACCTTGTTACGACTT-3' primers on ABI 9700
 139 Applied Biosystems thermal cycler at a final volume of 50 µl for 35 cycles. The PCR mix included: X2
 140 Dream Taq Master Mix supplied by Inqaba, South Africa (Taq polymerase, DNTPs, MgCl), the primers at
 141 a concentration of 0.4 M and the extracted DNA as template. The PCR conditions were as follows: Initial
 142 denaturation, 95°C for 5 min; denaturation, 95°C for 30 sec; annealing, 52°C for 30 sec; extension, 72°C
 143 for 30 sec for 35 cycles and final extension, 72°C for 5 min. The product was resolved on a 1% agarose
 144 gel at 120V for 15 min and visualized on a UV transilluminator.

145 **2.5.5 Restriction Endonuclease digestion of amplified 16S rRNA Gene**

146 The endonuclease **of the amplified 16SrRNA** gene was digested using *BsGr* following the manufacturer's
 147 instruction as follows: 2 µl of enzymes solution was added to 36 µl of reaction mixture (10 mMTris-HCl
 148 (pH 7.8), 5 mM MgCl₂, 20 mMNaCl, 10 mM 2-mercaptoethanol, 10 µg/ml albumin), followed by 2 µl
 149 amplified 16S rRNA gene. The mixture was incubated at 37°C for 1 h; and the restriction fragment were

150 separated in 1% agarose gel and visualized on a UV transilluminator.

151 **2.5.6 Agarose Gel Electrophoresis**

152 The agarose gel electrophoretic assay for detection of amplified genes for different DEC pathotypes was
153 carried out as described [16]. Briefly, 8µl of PCR products stained with ethidium bromide was loaded into
154 1.0% (wt/vol) agarose gel wells with a molecular marker run concurrently at 120 V for 30 min. The DNA
155 bands were visualized and photographed under UV light 595nm.

156 **3. RESULTS AND DISCUSSION**

157 **3.1 Isolation and Identification of *Escherichia coli***

158 The cultural, morphological and biochemical finger print of *E. coli* isolated from stool of suspected
159 diarrheic patients in Dalhatu Araf Specialist Hospital, Lafia (DASHL), Federal Medical Centre, Keffi
160 (FMCK) and General Hospital, Keffi, Nigeria is as shown in Table 3. Pinkish colony on MCA which grew
161 with greenish metallic sheen on EMB agar was Gram negative rod and had biochemical reactions
162 namely: indole-positive, methyl red-positive, Voges-Proskauer-negative, citrate-negative, ONPG-positive,
163 among others indicated *E. coli*.

164 **3.2 Occurrence of *Escherichia coli***

165 The occurrence of *Escherichia coli* from stool of patients with suspected cases of diarrhea in the selected
166 health facilities in Nasarawa State, Nigeria is as shown in Figure 1. All (100%) stool samples collected
167 (207) harbored *E. coli* in all the hospitals. The occurrence in relation to age and gender is distributed as
168 shown in **Table 4 and 5** respectively.

169 **3.3 Molecular Detection of Extended Spectrum Beta-Lactamase**

170 The molecular detection of ESBL production in *E. coli* isolates is as shown in Table 6. Out of 56 isolates
171 jointly resistant to cefotaxime and/or ceftazidime and ciprofloxacin from DASHL, FMCK and GHA, 53.6%
172 (30/56) were ESBL producers, distributed in relation to the hospitals as follows: *bla*_{CTX-M} in DASHL was
173 6(66.7%), FMCK was 11(100.0%), and GHA was 10(100.0%); *bla*_{SHV} in DASHL was 8(88.9%), FMCK
174 was 7(63.6%), and GHA was 10(100.0%), and *bla*_{TEM} in DASHL was 9(100.0%), FMCK was 10(90.9%),
175 and GHA was 10(100.0%).

176 **3.4 Co-existence of the Extended Spectrum Beta-Lactamase Resistance Genes.**

177 The co-existence of the extended spectrum beta-lactamase resistance genes in relation to the hospitals
178 as follows: DASHL *bla*_{CTX-M/SHV/TEM} 6(66.7%), FMCK 6(54.5%) and GHA 10(100.0%); *bla*_{CTX-M/SHV} DASHL
179 1(11.1%), FMCK 1(9.1%) and GHA 0(0.0%); *bla*_{CTX-M/TEM} DASHL 0(0.0%), FMCK 4(36.4%), GHA
180 0(0.0%); *bla*_{SHV/TEM} DASHL 2(22.2%), FMCK 0(0.0%) and GHA 0(0.0%) and *Bla*_{TEM} DASHL 1(11.1%),
181 FMCK 0(0.0%) and GHA 0(0.0%) as shown in Table 7. Occurrence of Diarrhegenic *Escherichia coli*
182 genes in Extended Spectrum Beta-Lactamase Resistance *Escherichia coli* from the stool of the patients is
183 as shown in Table 8.

184 **3.5 Distribution of Strains of Extended Spectrum Beta-Lactamase Resistant**
185 **Diarrhegenic *Escherichia coli*.**


186 The distribution of ESBL resistant diarrhegenic *E. coli* into different strains base on their RFLP pattern is
187 as shown in Table 9. The isolates were distributed into strain A – J and the occurrence of strain A was
188 high in GHA (70.0%) but low in DASHL (33.3%). The percentage distribution of strain D, F, H, I, and J
189 were 11.1% in DASHL while the occurrence of I was 18.2% in FMCK. In addition the occurrence of
190 strains C, D, and G were 9.1% in FMCK while the occurrence of C, E, and G were 10.0% in GHA.

191

192 **Table 3:** Cultural, Morphological and Biochemical characteristics of *Escherichia coli* from stool of patients with suspected cases of
 193 diarrhea in Nasarawa State.

Cultural characteristics	Morphological characteristics		Biochemical Characteristics										Inference		
	Gram reaction	Morphology	IND	MR	VP	CT	TDA	ONPG	LYS	ORN	UR	NT		H ₂ S	MAL
Pinkish colonies on MCA and Greenish metallic sheen on EMB agar	-	Rod	+	+	-	-	-	+	+	+	-	+	-	-	<i>E. coli</i>

194 + = Positive, - = negative, IND = Indole; MR = Methyl red; Vp = Voges-Proskauer, CT = Citrate, LYS = Lysine, ORN = Ornithine; ONPG = Ortho-Nitrophenyl-β-galactosidase, UR =
 195 Urease, NT = Nitrate, H₂S = Hydrogen Sulphide, Mal = Malonate, TDA = Phenylalanine deaminas



196

197 **Figure 1:** Occurrence of *Escherichia coli* from stool of patients with suspected cases of diarrhea in
 198 Nasarawa State in relation to Hospital (DASHL= Dalhatu Araf Specialist Hospital Lafia, FMCK= Federal
 199 Medical Centre Keffi, GHA= General Hospital Akwanga).

200

201 **Table 4:** Occurrence of *Escherichia coli* in the stool of patients in relation to Age

Age (Years)	No. of Samples			No. (%) <i>Escherichia coli</i>		
	DASHL	FMCK	GHA	DASHL	FMCK	GHA
0-5	28	23	29	28(100.0)	23(100.0)	29(100.0)
6-10	17	18	16	17(100.0)	18(100.0)	16(100.0)
11-15	5	6	5	5(100.0)	6(100.0)	5(100.0)
16-20	8	6	1	8(100.0)	6(100.0)	1(100.0)
21-25	4.0	0.0	2.0	4.0(100)	0.0(0.0)	2.0(100)
26-30	6.0	3.0	5.0	6.0(100)	3.0(100)	5.0(100)
31-35	0.0	0.0	6.0	0.0(0.0)	0.0(0.0)	6.0(100)
36-40	0.0	1.0	0.0	0.0(0.0)	1.0(100)	0.0(0.0)
41-45	0.0	5.0	0.0	0.0(0.0)	5.0(100)	0.0(0.0)
>45	1.0	7.0	5.0	1.0(100)	7.0(100)	5.0(100)
Total	69	69	69	69(100)	69(100)	69(100)

202 DASHL= Dalhatu Araf Specialist Hospital, Lafia; FMCK= Federal Medical Centre Keffi; GHA= General Hospital, Akwanga;
 203 No.=Number, %= Percentage.

204

205

206 **Table 5** Occurrence of *Escherichia coli* in the stool of patients in relation to Gender

Gender	No. of Sample			No. (%) <i>E. coli</i>		
	DASHL	FMCK	GHA	DASHL	FMCK	GHA
Male	27	33	29	27(100.0)	33(100.0)	29(100.0)
Female	42	36	40	42(100.0)	36(100.0)	40(100.0)
Total	69	69	69	69(100.0)	69(100.0)	69(100.0)

207 DASHL= Dalhatu Araf Specialist Hospital Lafia; FMCK= Federal Medical Centre, Keffi; GHA= General Hospital, Akwanga; No. =
 208 Number; % = Percentage.

209

210 **Table 6:** Molecular detection of Extended Spectrum Beta-Lactamase Resistance Genes in phenotypically
 211 confirmed ESBL producing *Escherichia coli* from the stool of the patients

ESBL Resistance Genes	No. (%) Isolates		
	DASHL (n=9)	FMCK (n=11)	GHA (n=10)
<i>bla_{CTX-M}</i>	6(66.7)	11(100.0)	10(100.0)
<i>bla_{SHV}</i>	8(88.9)	7(63.6)	10(100.0)
<i>bla_{TEM}</i>	9(100)	10(90.9)	10(100.0)

212 DASHL= Dalhatu Araf Specialist Hospital, Lafia; FMCK= Federal Medical Centre, Keffi; GHA= General Hospital, Akwanga;
 213 No.=Number; %= Percentage.

214

215 **Table 7:** Co-existence of the Extended Spectrum Beta-Lactamase Resistance Genes in the *Escherichia*
 216 *coli* from the stool of the patients

ESBL Resistance Genes	No. (%) Isolates		
	DASHL (n=10)	FMCK (n=11)	GHA (n=10)
<i>bla_{CTX-M/SHV/TEM}</i>	6(66.7)	6(54.5)	10(100.0)
<i>bla_{CTX-M/SHV}</i>	1(11.1)	1(9.1)	0(0.0)
<i>bla_{CTX-M/TEM}</i>	0(0.0)	4(36.4)	0(0.0)
<i>bla_{SHV/TEM}</i>	2(22.2)	0(0.0)	0(0.0)
<i>Bla_{TEM}</i>	1(11.1)	0(0.0)	0(0.0)

217 DASHL= Dalhatu Araf Specialist Hospital, Lafia; FMCK= Federal Medical Centre, Keffi; GHA= General Hospital, Akwanga;
 218 No.=Number; %= Percentage.

219

220

221

222

223 **Table 8:** Occurrence of Diarrhegenic *Escherichia coli* genes in Extended Spectrum Beta-Lactamase
 224 Resistance Producing *Escherichia coli* from the stool of the patients

Hospitals	ESBL Producers	No. (%) of DEC Pathotypes					Total (%) DEC
		ETEC	EHEC	EPEC	EIEC	EAEC	
DASHL	9	2(22.2)	0(0.0)	0(0.0)	1(11.1)	5(55.6)	8(88.9)
FMCK	11	4(36.4)	2(18.2)	0(0.0)	3(27.3)	9(81.8)	18(61.1)
GHA	10	6(60.0)	4(36.4)	0(0.0)	0(0.0)	7(70.0)	17(58.8)
Total	30	12(40.0)	6(20.0)	0(0.0)	4(13.3)	21(70.0)	

225 ESBL= Extended Spectrum Beta-lactamase; DEC= Diarrhegenic *E. coli*; ETEC= Enterotoxigenic *E. coli*; EHEC=
 226 Enterohemorrhagic *E. coli*; EPEC= Enteropathogenic *E. coli*; EIEC= Enteroinvasive *E. coli*; EAEC= Enteroaggregative *E. coli*;
 227 DASHL= Dalhatu Araf Specialist Hospital, Lafia; FMCK= Federal Medical Centre, Keffi; GHA= General Hospital, Akwanga;
 228 No.=Number; %= Percentage.

229

230 **Table 9:** Distribution of different strains of Extended Spectrum Beta-Lactamase diarrhegenic *Escherichia*
 231 *coli* from the stool of the patients

Stains	No. (%) Isolates		
	GHA (n=10)	FMCK (n=11)	DASHL (n=9)
A	7(70.0)	6(54.5)	3(33.3)
B	0(0.0)	0(0.0)	1(11.1)
C	1(10.0)	1(9.1)	0(0.0)
D	0(0.0)	1(9.1)	1(11.1)
E	1(10.0)	0(0.0)	0(0.0)
F	0(0.0)	0(0.0)	1(11.1)
G	1(10.0)	1(9.1)	0(0.0)
H	0(0.0)	0(0.0)	1(11.1)
I	0(0.0)	2(18.2)	1(11.1)
J	0(0.0)	0(0.0)	1(11.1)

232 ESBL= Extended Spectrum Beta-lactamase; DASHL= Dalhatu Araf Specialist Hospital, Lafia; FMCK= Federal Medical Centre, Keffi;
 233 GHA= General Hospital, Akwanga; No.=Number; %= Percentage.

234




235

Plate 2: Agarose gel electrophoresis of the 16S rRNA gene of ESBL *E. coli* isolates from DASHL. Lanes D1-D9 represents the 16SrRNA gene bands (1500bp), Lane N represents the negative control, and lane M represents the 1500bp molecular ladder.

236

237

F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 N M



16SrRNA gene (1500bp)

1500bp

238


Plate 3: Agarose gel electrophoresis of the 16S rRNA gene of ESBL *E. coli* isolates from FMCK. Lane F1, failed amplification, Lanes F2-F11 represents the 16SrRNA gene bands (1500bp), Lane N represents the negative control, lane M represents the 1500bp molecular

239

240

241

G1 G2 G3 G4 G5 M G6 G7 G8 G9 G10



16SrRNA gene (1500bp)

1500bp

242


Plate 4: Agarose gel electrophoresis of the 16S rRNA gene of ESBL *E. coli* isolates from GHA. Lanes G1-G10 represents the 16SrRNA gene bands (1500bp), Lane M represents the 1500bp molecular ladder.

243

244

245

1 2 3 M 4 5 6 7 8 9 10




*bla*_{TEM}(960bp)

1000bp

246

Plate 5: Agarose gel electrophoresis of the amplified *bla*_{TEM} genes from the *E. coli* isolates from DASHL. Lanes 1, 2, 3, 4, 5, 6, 8, 9 and 10 represent the *bla*_{TEM} bands, Lane M represents the 1500bp molecular ladder, while other lanes show no bands.



247


Plate 6: Agarose gel electrophoresis of the amplified *bla_{SHV}* gene from the *E. coli* isolates DASHL. Lanes 2, 3, 4, 5, 6, 7, 8 and 9 represent the *bla_{SHV}* bands, Lane M represents the 1500bp molecular ladder, while other lanes show no bands.

248

249

250

251



252


Plate 7: Agarose gel electrophoresis of the amplified *bla_{CTX-M}* gene from the *E. coli* isolates DASHL. Lanes 2, 3, 4, 5, 6 and 9 represent the *bla_{CTX-M}* bands, Lane M represents the 1500bp molecular ladder, while other lanes show no bands.

253

254

255

256




257

Plate 8: Agarose gel electrophoresis of the amplified *bla_{TEM}* genes from the *E. coli* isolates from FMCK. Lanes 1- Lane 9- Lane11 represent the *bla_{TEM}* bands, Lane M represent the 1500bp molecular ladder, while Lane 8 showed no bands.

258

259

260




261

262

Plate 9: Agarose gel electrophoresis of the amplified *bla_{SHV}* genes from the *E. coli* isolates from FMCK. Lanes 1, 3, 4, 6, 8, 9 and 10 represent the *bla_{SHV}* bands, Lane M represents the 1500bp molecular ladder, while other lanes show no bands.

263

264



265


266

Plate 10: Agarose gel electrophoresis of the amplified *bla_{CTX-M}* gene from the *E. coli* isolates FMCK Lanes 1-Lane 11 represent the *bla_{CTX-M}* bands, Lane M represents the 1500bp molecular ladder.

267

268

269



270

Plate 11: Agarose gel electrophoresis of the amplified *bla_{TEM}* genes from the *E. coli* isolates from GHA. Lanes 1 – Lane 4 and Lane 7 - Lane 10 represent the *bla_{TEM}* bands, Lane M represents the 1500bp molecular ladder, while Lane 6 showed no band.




Plate 12: Agarose gel electrophoresis of the amplified *bla_{SHV}* genes from the *E. coli* isolates from GHA. Lanes 1-Lane 10 represent the *bla_{SHV}* bands, Lane M represents the 1500bp molecular ladder.




Plate 13: Agarose gel electrophoresis of the amplified *bla_{CTX-M}* gene from the *E. coli* isolates GHA. Lanes 1-Lane 10 represent the *bla_{CTX-M}* bands, Lane M represents the 1500bp molecular ladder.





Plate 14: Agarose gel electrophoresis of the diarrheagenic *Escherichia coli* pathotypes from stools of diarrheic patients in Nasarawa State, Nigeria. Amplification; L1, L4 & L6=*ial* (EIEC); L2, L8-L12, L14, L16 & L17=*pCVD* (EAEC); L15= *E. coli* (ATCC 11775); L18-L19= *eaeA*(EHEC); L21 *Elt* (ETEC); L23= negative; M= 1500bp; while L7, L13 & L22 showed no band.

285

286

1 2 3 4 5 6 7 8 9 10 11 12 M 13 14 15 16 17 18 19 20 21 22 23




287

288 **Plate 15:** RFLP Agarose gel electrophoresis of the 16S rRNA gene of the *Escherichia coli*
289 isolates from DASHL, FMCK and GHA showing different bands pattern after digestion
with *BsGr*.

290

291

UNDER PEER REVIEW



293 **Figure 2:** Dendrogram of 16srRNA of Extended Spectrum Beta-lactamase producing *Escherichia coli*
294 after digestion with endonuclease *BsGr*.

295

296 The number of infections due to ESBL *E. coli* is increasing, especially in African countries [17].

297 Diarrheagenic *Escherichia coli* (DEC) are important intestinal pathogens causing a wide variety of

298 gastrointestinal diseases, particularly among children in developing countries [18]. Studies on molecular

299 diversity and extended spectrum beta-lactamase resistance of diarrheagenic *Escherichia coli* isolated

300 from diarrhetic patients in Nasarawa State, Nigeria was carried out. The isolation of *E. coli* in all stool

301 samples(100%)in the study locations is in agreement with studies reported [4, 7, 18]; and confirms the

302 fact that *E. coli* is a common bacteria isolated in stool of human.

303 The occurrence of *Escherichia coli* from stool of patients with suspected cases of diarrhea in relation to
304 age; age group 0-5 and 6-10 years have the highest number of samples collected while age group 35 –
305 >45 have the least number collected. However, it was observed that between age groups the presence of
306 the bacterial isolates with age group 0-5 and 6-10 years having the highest occurrence of bacterial
307 isolates and the least is age group 35 – >45. This follows the same trend with a study done in Abuja [4,
308 19], which shows that diarrhea is statistically associated with age and majority of the cases occurring in
309 children between 7 months and 2 years of age. The reason for high incidence of bacteria isolates in age
310 group 0-5 and 6-10 years could be due to the fact that children within this age group on their own cannot
311 differentiate between what to eat and what not to eat; they have not learnt the rudiment of adherence to
312 aseptic or hygienic practice; they can barely express themselves. Most diarrhea occur during the first 2
313 years of life due to combined effects of declining levels of maternally acquired antibodies, the lack of
314 active immunity in the infant, the introduction of food that may be contaminated with faecal bacteria and
315 direct contact with human or animals faeces when the infant start to grow [4, 19]. Most enteric pathogens
316 stimulate at least partial immunity against repeated infection or illness, which helps to explain the
317 declining incidence of disease in older children and adults [20].

318 The occurrence of ESBL producers in *E. coli* isolates jointly resistant to ceftazidime and cefotaxime
319 observed in this study was higher than 26.3% reported [21], 16.5% reported in Egypt [22]. This study
320 showed that *bla*_{TEM}, *bla*_{SHV} and *bla*_{CTX-M} ESBL gene were expressed in GHA followed by FMCK and
321 DASHL. This finding does not in agree with the study earlier described [23]. The occurrence of *bla*_{CTX-M}
322 and *bla*_{TEM} genes was higher in all study location than *bla*_{SHV} and this finding seems to agree with the
323 study reported [22, 24]. The occurrence of *bla*_{TEM}, *bla*_{SHV} and *bla*_{CTX-M} ESBL gene observed in this study is
324 higher than that reported [25]. Observation from this study indicated that not all the *E. coli* isolate jointly
325 resistance to both cefotaxime and ceftazidime were ESBL producers and this finding is also in agreement
326 with the study earlier reported [26]. However, the mechanism of resistance to *E. coli* isolates that were
327 jointly resistance to both cefotaxime and ceftazidime may not be due to production of ESBL but may be
328 due to other mechanisms of metabolic resistance.

329 The Restriction Fragment Length Polymorphism (RFLP) of diarrheagenic *E. coli* of amplified 16S rRNA
330 gene digested with *BsGr* enzymes were distributed into strain A – J and the occurrence of strain A was

331 high in GHA (70.0%) but low in DASHL (33.3%). The percentage distribution of strain D, F, H, I, and J
332 were 11.1% in DASHL while the occurrence of I was 18.2% in FMCK. In addition, the occurrence of
333 strains C, D, and G were 9.1% in FMCK while the occurrence of C, E, and G were 10.0% in GHA.

334 The RFLP amplified *16SrRNA* gene digested with *BsGr* is the first study ever conducts in Nasarawa
335 State, Nigeria. However other similar studies on diarrheagenic *E. coli* have been reported elsewhere.

336 The high frequency of detection of EAEC 81.8% in FMCK, 70.0% in GHA and 55.6% in DASHL observed
337 in this study was not surprising. It is in agreement with 7.2% [9] and 22.0% [7], earlier reported in Kenya
338 and Keffi (in Nigeria). EAEC was previously reported to be endemic in Southern Nigeria as well as in sub-
339 Saharan Africa [27]. So, our observation on the occurrence of EAEC 9(81.8) in FMCK, 7(70.0) in GHA
340 and 5(55.6) in DASHL concurred with what was reported in Southwestern Nigeria and elsewhere
341 especially in the sub-Saharan Africa 18(7.2%) [27].

342 The frequency of detection of EAEC in this study is higher than that reported [28]; but the detection of
343 ETEC 4(36.4) in FMCK, 6(60.0) in GHA and 2(22.2) in DASHL and EIEC3(27.3) in FMCK and 1(11.1) in
344 DASHL followed by EHEC 4(36.4) in GHA and 2(18.2) in FMCK were low (1.0 and 1.9%) reported [9, 28]
345 respectively. The very low frequency of detection of diarrheagenic *E. coli* obtained in this study is in close
346 agreement with the study reported [29] with prevalence of *E. coli* O157: H7 in children with diarrhea as
347 5.4% in Zaria, Nigeria. Also, [30, 31], reported a prevalence of 5% EHEC O157:H7 in humans, in Lagos,
348 Nigeria. But it is in contrast with the study conducted [32], who reported 19.6% prevalence of
349 diarrheagenic *E. coli* in a study conducted in Southeastern Nigeria. An incidence higher than 40% has
350 been reported in Bangladesh by [33]. It was observed that EPEC were not detected in any of the study
351 location, reason may be so because isolation rate of different pathotypes of diarrheagenic *E. coli* have
352 been reported to be vary in different geographical areas although other studies in other parts of the
353 country reported low frequency of detection of EPEC [28, 33], which is in total disagreement with studies
354 carried out in Southeast Nigeria, which reported that EPEC was the most isolated of all DEC pathotypes
355 followed by EAEC, ETEC, EIEC and EHEC in that order [32].

356 Outbreaks and sporadic cases of EHEC have been reported in developed countries of North America,
357 Japan, Europe and even Australia [34]. However there have been few reports of sporadic EHEC in
358 African countries. Three large EHEC outbreaks were previously reported in Swaziland, Central African

359 Republic and the Cameroon [34, 35]; but some authors criticized the methodology used in those studies
360 as being nonspecific or insensitive [27]. Despite this, our findings tend to align with the earlier observation
361 that EPEC and EHEC may be rare after all [32, 35].The patients employed in this study may be infected
362 by other pathogens other than diarrheagenic *E. coli* since there are different pathogens that can cause
363 diarrhea in children and adults.

364 **4. CONCLUSION**

365 Diarrheagenic *Escherichia coli* was found in all the study locations; and mostly among children within the
366 Age group 0-5 and 6-10 years and were antibiotic resistance as well as ESBL resistant. The predominant
367 ESBL and pathotypes genes were *bla*_{CTX-M}, *bla*_{TEM} and EAEC.

368 **ETHICAL APPROVAL**

369 All authors hereby declare that all experiments have been examined and approved by the appropriate
370 ethics committee and have therefore been performed in accordance with the ethical standards laid down
371 in the 1964 Declaration of Helsinki.

372 **CONSENT**

373 The informed written consents of the suspected diarrheic patients were obtained before sample
374 collection.

375

376 **REFERENCES**

- 377 1. World Health Organization (2017).
- 378 2. Nweze EI. Virulence Properties of Diarrhoeagenic *E. coli* and Etiology of Diarrhoea in Infants,
379 Young Children and Other Age Groups in Southeast, Nigeria. American-Eurasian Journal of
380 Scientific Research, 2009; 4(3):173-179.
- 381 3. Ali MMM, Ahmed SF, Klena JD, Mohamed ZK, Moussa TAA, Ghenghesh KS. Enteroggregative
382 *Escherichia coli* in diarrheic children in Egypt: molecular characterization and antimicrobial
383 susceptibility. Journal of Infection Developing Countries, 2014; 8(5):589-596.
- 384 4. Onanuga A, Igbeneghu O, Lamikanra A. A study of the prevalence of diarrhoeagenic *Escherichia*
385 *coli* in children from Gwagwalada, Federal Capital Territory, Nigeria. Pam African Medical
386 Journal, 2014; 17:146.
- 387 5. Chen HD, Frankel G. Enteropathogenic *Escherichia coli*: unraveling pathogenesis. *FEMS*
388 *Microbiological Review*; 2014; 29: 83-98.
- 389 6. Sani A, Onaolapo JA, Ibrahim YKE, Idris HW, Igwe JC, Nworie A. Prevalence of *Escherichia coli*
390 pathotypes among children with diarrhoea in Zaria, Nigeria; *British Journal of Medicine and*
391 *Medical Research*, 2015; 7:17-24.

- 392 7. Abimiku RH, Ngwai YB, Nkene IH, Taffeng YM. Molecular detection of diarrheagenic pathotypes
393 of *Escherichia coli* from diarrheic patients in Keffi, Nigeria. *Microbioz Journals, Journal of*
394 *Microbiology and Biomedical Research*, 2016; 2 (3),1-6.
- 395 8. Puño-Sarmiento J, Medeiros L, Chiconi C, Martins F, Pelayo J, Rocha S. Detection of
396 diarrheagenic *Escherichia coli* strains isolated from dogs and cats in Brazil. *Veterinary*
397 *Microbiology*; 2013; 166: 676–80.
- 398 9. Nguyen TV, Le VP, Le, HC, Gia KN, Weintraub A. Detection and characterization of
399 diarrheagenic *Escherichia coli* from young children in Hanoi, Vietnam. *Journal of Clinical*
400 *Microbiology*, 2005; 43(2):755-760.
- 401 10. Bautista DH, Gómez CA, Rangel VE, Vázquez BE, Castro RJ. Frequency of indicator
402 bacteria, *Salmonella* and diarrhoeagenic *Escherichia coli* pathotypes on ready-to-eat cooked
403 vegetable salads from Mexican restaurants. *Letters of Applied Microbiology*, 2013; 56: 414–20.
- 404 11. Cheesbrough M. *District Laboratory practice in Tropical Countries*, Cambridge University United
405 Kingdom, Part 2, 2006; 63–70.,
- 406 12. *Clinical and Laboratory Standards Institute (CLSI)*. 2015.
- 407 13. Jarlier V, Nicolas MH, Fournier G, Extended broad-spectrum β -lactamases conferring
408 transferable resistance to newer β -lactam agents in Enterobacteriaceae: hospital prevalence and
409 susceptibility patterns. *Review of Infectious Diseases*, 1998; 10: 867-8.
- 410 14. Croxen MA, Law RJ, Scholz R. Recent advances in understanding enteric
411 pathogenic *Escherichia coli*. *Clinical Microbiology Review*; 2013; 26:822–880.
- 412 15. Feizabadi MM, Delfani S, Raji N, Majnooni A, Aligholi M, Shahcheraghi F, *et al*. Distribution of bla
413 TEM, bla SHV, bla CTX-M genes among clinical isolates of *Klebsiella pneumoniae* at
414 Labbafinejad Hospital, Tehran, Iran. *Microbial Drug Resistance*, 2010; 16(1):49-53.
- 415 16. Toma CY, Lu N, Higa N, Nakasone I, Chinen A, Baschkier M, Rivas
416 M. Multiplex PCR assay for identification of human diarrheagenic *Escherichia coli*. *J. Clin.*
417 *Microbiol.* 2003; 41: 2669–2671.
- 418 17. Akbariqomi M, Ghafourian S, Taherikalani M, Mohammadi S, Pakzad I, Sadeghifard N. Antibiotic
419 Susceptibility Patterns of Extended Spectrum Beta-Lactamase and Non Extended Spectrum
420 Beta-Lactamase *Pseudomonas aeruginosa* Clinical Isolates. *Recent Patents on Anti-infective*
421 *Drug Discovery*, 2015; 10(2), 128-133.
- 422 18. Ali MMM, Ahmed SF, Klena JD, Mohamed ZK, Moussa TAA, Ghenghesh KS. Enteroaggregative
423 *Escherichia coli* in diarrheic children in Egypt: molecular characterization and antimicrobial
424 susceptibility. *Journal of Infection Developing Countries*, 2014;8(5):589-596.
- 425 19. Ifeanyi CI, Isu RN, Akpa AC, Ikeneche NF. Enteric bacteria pathogens associated with diarrhoea
426 of children in the federal capital territory Abuja, Nigeria. *New York Science Journal*; 2010; 3(1).
- 427 20. Abdullahi M, Olonitola SO, Inabo IH. Isolation of bacteria associated with
428 diarrhoea among children attending some hospitals in Kano Metropolis, Kano State, Nigeria.
429 *Bayero Journal of Pure and Applied Sciences*. 2010;3(1):10–15.
- 430 21. Fody AM, Boubou L, Moussa A, Bawa HI, Konate A, Yaou C, Zongo C, Salaou C, Daouda A,
431 Sidikou R, Traoure AB, Barro N. Phenotypic Detection of ESBL in multidrug resistant *E. coli* from
432 clinical isolates in Niamey, Niger. *Africa .Final Microbiology Research*, 2017; 713-717.
- 433 22. Ahmed OL, Ahmed SA, Ahmed IZ. Detection of blaSHV and blaCTX-M genes in ESBL producing
434 *Klebsiella pneumoniae* isolated from Egyptian patients with suspected nosocomial infections.
435 *Egyptian Journal of Medical Human Gene*, 2013; 14:283-297.
- 436 23. Sedighi I, Mohammad RA, Ali R, Zahra K, Mohammad YA. Dissemination of Extended-Spectrum
437 β -Lactamases and Quinolone Resistance Genes among Clinical Isolates of Uropathogenic
438 *Escherichia coli* in Children. *Jundishapur Journal of Microbiology*, 2015; 8(7): 1-6.
- 439 24. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. *Antimicrobial Agent*
440 *Chemotherapy*; 2010; 54: 965-967.

- 441 25. Mohadjer S, Bidanjiri A, Hafezi R, Hamidi AH. The first report on the isolation of enterotoxigenic
442 *Escherichiacoli* as a cause of infantile diarrhea in Iran; Iranian Journal of Public Health,1982;
443 11: 77-88.
- 444 26. Nkene IH, Ngwai YB, Omede MU, Samuel J, Envuladu EY, Abimiku RH. Extended spectrum
445 beta-lactamase production in *Escherichia coli* from urine of symptomatic and asymptomatic
446 subjects in Keffi, Nigeria. International Journal of Research Studies in Biosciences, 2015;
447 3(12):19-25.
- 448 27. Okeke IN. Diarrheagenic *Escherichia coli* in sub-Saharan Africa: status, uncertainties and
449 necessities. Journal of Infectious in Developing Countries; 2009; 3: 817- 842.
- 450 28. Sani A, Onalapo JA, Ibrahim YKE, Idris HW, Igwe JC, Nworie A. Prevalence of *Escherichia coli*
451 pathotypes among children with diarrhoea in Zaria, Nigeria; British Journal of Medicine and
452 Medical Research, 2015; 7:17-24.
- 453 29. Scaletsky ICA, Aranda KRS, Souza TB, Silva NP. Adherence factors in atypical
454 enteropathogenic *Escherichia coli* strains expressing the localised adherence-like pattern
455 in Hep-2 cells. *J Clinical Microbiology*; 2010; 48: 302-306.
- 456 30. Ogunsanya TI, Rotimi VO, Adenuga AA. Study of the aetiological agents of childhood diarrhoea
457 in Lagos, Nigeria. *J Med Microb*; 2009.40:10–14.
- 458 31. Olorunshola ID, Smith SI, Coker AO. Prevalence of EHEC O157:H7 in patients with diarrhoea
459 inLagos, Nigeria. *Acta Pathologica Microbiologica Scandinavica*, 2000; 108:761-
460 763.
- 461 32. Nweze EI. Virulence Properties of Diarrhoeagenic *E. coli* and Etiology of Diarrhoea in Infants,
462 Young Children and Other Age Groups in Southeast, Nigeria. *American-Eurasian Journal of*
463 *Scientific Research*, 2009; 4(3):173-179.
- 464 33. Albert MJ, Faruque AS, Faruque SM, Sack RB, Mahalanabis, D. Case-control study of
465 enteropathogens associated with childhood diarrhoea in Dhaka, Bangladesh. *J Clin.*
466 *Microbio*1999; 37:3458-3464.
- 467 34. Effler E, Isaaˆcson ML, Arntzen RH, Canter TP, Barrett L, Lee C, Mambo W, Levine AZ, Griffin
468 PM. Factors contributing to the emergence of *Escherichia coli* O157 in Africa *Emerging Infect Dis*
469 2001; 7: 812-819.
- 470 35. Germanii YB, Soro MV, Morel OJM. Enterohaemorrhagic *Escherichia coli* in the Central
471 African Republic *Lancet*1997; 349: 1670
472

473